The Journal of Informed Pharmacotherapy

informed pharmacotherapy

The World’s First Peer Received online journal Dedicated to Pharmacotherapy

Responsibilities of Reviewers

Filter out flawed work and prevent its publication

Assist the Editors and the author(s) to improve the quality & importance of the work:

  • evaluate originality, quality, and importance of the paper
  • identify errors, misinterpretation, overinterpretation, and “crimes of passion” committed by authors
  • fill in missing information, or at least identify its omission
  • support your comments with appropriate references if necessary
  • in addition to identifying faults, positive comments are appreciated as well.
  • DO NOT provide line-by-line comments on grammar and spelling. Global comments like “many spelling/grammar” errors is all that is needed. This is not the most efficient use of your time.

ALWAYS inform us of Potential Conflicts of Interest

In your review, point out areas which you are not qualified to comment on (lack of comment implies correctness, which may not be appropriate).

Inform us if you have previously reviewed this paper for another journal. This way we can determine whether it has been significantly revised prior to submission to JIP.

Respect that the manuscript is a privileged communication, is confidential, and for your eyes only. We do, however, encourage you to consult your colleagues who may have useful input to provide.

Be PROMPT in the completion of your review.

  • Inform us immediately if you cannot complete the review by the deadline.
  • Your referral of the manuscript to another qualified reviewer is appreciated if you are unable to review it by the deadline.


This is an independent, non-profit and subscription-free journal. We do not accept advertising and we rely heavily on the voluntary contributions of our publishing editors and our international editorial board. We currently operate without external sponsorship.

Frequently Asked Questions about the Journal of Informed Pharmacotherapy

What is the JIP?

  • The JIP is a peer-reviewed online journal dedicated to the practice of rational pharmacotherapy through the use of evidence-based principles.
  • The JIP fosters the rapid widespread dissemination of original research findings, as well as information intended to help pharmacotherapy practitioners (i.e. pharmacists, physicians, nurses and other health care providers) provide better care for their patients.

Why was the JIP created?

  • The idea for the Journal arose out of a recognized need for the following:
  • A new peer-reviewed journal that focuses on pharmacotherapy
  • A journal that provides pharmacotherapy literature reviews which highlight, condense, interpret and put this information into proper perspective using evidence-based principles.
  • An alternative to traditional hardcopy distribution to facilitate the rapid and worldwide dissemination of original research activity reports.
  • A journal that is accessible to all, for a price that all can afford

What is the history of the JIP?

The idea for the JIP was originated in late 1998 by the Founding Editors (top left of this page). Since then, the Founding Editors have been busy forming an editorial board and the processes by which the JIP will fulfill its mission.

Who is expected to read the JIP?

The JIP is intended for any health care professional with an interest in optimizing pharmacotherapy.

What makes the JIP unique?

  • JIP is the only peer-reviewed online journal devoted entirely to pharmacotherapy
  • JIP provides a strong evidence-based perspective through peer-reviewed research and reviews of the pharmacotherapy literature which put the research findings into their proper context
  • JIP provides a venue for clinicians to widely disseminate research findings (the second it is placed on the Web, it is accessible from any internet terminal on the planet).
  • JIP provides more rapid dissemination of information than traditional print journals (for example, we expect turnaround time for articles to be a few weeks, vs. a few months for old-style journals)
  • JIP does not require a paid subscription to access

Is the JIP linked to the Pharmaceutical Industry?

  • No. There is no financial relationship between the JIP and any pharmaceutical company.
  • As with other respected peer-reviewed journals, relationships between authors and such companies must be declared in writing at the time of submission and the details will be provided to the readership in conjunction with any resulting publications.

How is the JIP organized?

  • The day-to-day operations of the JIP are run by the Founding Editors on a voluntary basis.
  • Section Editors have been selected based upon their recognized clinical and research expertise in a specific area of pharmacotherapeutics (e.g.. cardiology, infectious diseases, toxicology, etc.)
  • Section Editors are drawn mainly from the United States and Canada.
  • Expert reviewers have been drawn from the global pool of pharmacotherapeutics practitioners and researchers.

What are the responsibilities of JIP Section Editors?

  • As a Section Editor, commitment to the following is required:
  • A new peer-reviewed journal that focuses on pharmacotherapy
  • Coordinate the assessment of submissions related to your area of specialty. This involves approximately 2-3 submissions per year.
  • Identify and facilitate the involvement of 2-3 reviewers for each submission sent to you.
  • Provide your own recommendation as to the suitability of each submission for publication.
  • By invitation or voluntarily provide other input related to your specialty area such as evidence-based reviews of the pharmacotherapeutic literature, reviews of websites or editorials.
  • Provide a review turnaround time of 4 weeks or less to ensure a prompt (but thorough) review of each submission.
  • Be conversant in the use of email (including the ability to send and receive file attachments) and the internet and have ready access to both. All submissions to the Journal must be in Microsoft Word 97/2000 format, so editors/reviewers must have access to and skills in using this word processing software.
  • Be willing to make a one year commitment to participation as a Section Editor.
  • Although these responsibilities may sound onerous, there are several Section Editors and most of the administrative duties are handled by the Managing/Founding Editors. Accordingly, the workload for Section Editors should be manageable.
  • Regardless of whether you are called upon to provide input to the Journal, you would be listed as a Section Editor in all issues of the Journal on the website.
  • More details about reviewer responsibilities.

What is the format of the JIP?

Articles will be published on the Web in browser-friendly HTML format and in a downloadable PDF (Adobe Acrobat) document format.

What types of information does the JIP contain?

Evidence-based reviews of the pharmacotherapeutic literature with emphasis on interpretation of the findings, designed to help practitioners put the findings into proper perspective. Written by experts in the field.

Articles from a variety of sources focusing on therapeutic reviews, practice-related issues, an controversies. These articles undergo editorial review prior to publishing.

An opportunity for researchers to rapidly disseminate their findings in abstract form.

Reviews of pharmacotherapy-related websites and other online clinical information resources. Designed to aid practitioners in finding high-quality information as well as using for the internet to enhance their practice.

Allows rapid interpretation, criticism, and discussion of articles in the Journal (or otherwise) by readers.

What about Permanence?

  • One of the primary problems with electronic publication is the difficulty guaranteeing permanence. For many, the fear that a journal may disappear after a short period of publication is enough to deter subscription or submission to that journal. This is particularly a problem for independent journals which often do not have the technical infrastructure or expertise to guarantee permanence.
  • The JIP will address this issue by using the Journal Backup service provided by the International Consortium for Alternative Academic Publishing (ICAAP) which provides a backup service which ensures the latest version of this publication will always be available at a central location. In addition to ensuring quick access, this also provides the service of ensuring continuity of access even if we discontinue publication.
  • The site will also be “mirrored” through the ICAAP mirroring service. With this service, I.C.A.A.P. provides fast North American mirrors for international users. Mirrors are essentially duplicate copies of the original publications housed on alternate servers. Users choose the server closest to their geographic location thereby increasing speed of access and visibility.

Why should authors consider submitting articles for publication in the JIP?

  • If accepted, authors can expect to have their articles available to a worldwide audience within a few weeks of submission
  • Authors will have their articles reviewed by established experts in their field
  • Authors can expect to be amongst the first to have articles published in a online peer-reviewed journal
  • Authors will support the principles of alternative academic publishing, thereby slowing the decay in our university library systems caused by exorbitant subscription fees charged by publication houses for traditional print journals.

How does the JIP peer-review process work?

Articles submitted for peer review will undergo a rigorous traditional peer review process intended to minimize the likelihood of release of scientifically unfounded or biased results while minimizing the time it takes to make valid results available.

Generally, the process looks something like this:

  1. Founding editors review submission for worthiness of external peer-review.
  2. If deemed worthy of peer-review, blinded review by at least two experts in the therapeutic area concerned is conducted.
  3. Feedback from reviewers is received by Founding Editors and publication-worthiness is assessed.
  4. If deemed potentially worthy of publication, comments and suggestions from reviewers are collated and conveyed to the author.
  5. If the author wishes to address the comments / concerns raised by the JIP reviewers, he/she edits the document as appropriate and sends it back to the founding editors.
  6. If the reviewer’s concerns have been substantially addressed, the article undergoes final editing and is released for publication. If there is still concern that the reviewers comments have not been properly addressed, the article may be sent back to the reviewers for their input.

See the JIP’s detailed peer-review algorithm in PDF format.

How are JIP citations referenced and cited?

  • Since issues of the JIP are dynamic in the sense that they are built up over time as the articles are completed, we have devised a system that should still make it easy to identify and cite JIP articles
  • Articles published during each calendar quarter (i.e. 3-month period) will be identified by year, issue (1-4) and page numbers according to the Vancouver
  • Page numbers will be assigned sequentially from the first article in the issue through to the closing date for that issue
  • Thus, JIP articles may be cited in the standard Vancouver Group format (e.g. J Inform Pharmacother 2000;3:45-52) or by using standard web citation formats, such as:
  • Marra C. Public Access Comput Syst Rev [serial on-line] 2000;3(4):109-15. Available from: Public Access Computer Systems Forum PACS-L via the Internet ( Accessed 29 Nov 1999.

How often is the JIP issued?

Unlike traditional print journals, articles in the JIP will be issued on a continuous basis. As soon as an article has completed the appropriate review process, it will be posted to the JIP website.
Delays related to episodic publishing (e.g. monthly editions) are avoided.

How much does it cost to subscribe to the JIP?

Nothing. The JIP will be accessible at no cost over the internet.
Users will only be required to have the necessary hardware/software for access purposes.
A free password-based “subscriber” access system may be set up in the future to allow us to track the nature of our readership, however, no information about our readers will be released to any other agency.


Canadian ePharmacies and the American Public: Mutualistic, Parasitic or Commensal Symbiosis?
Jewesson PJ

Email to the Editors
Readers respond to the editorial “Canadian ePharmacies and the American Public: Mutualistic, Parasitic or Commensal Symbiosis?”

Issues in Pharmacotherapy Practice contemporary issues by clinical practitioners

Canadian Online Pharmacies Serving U.S. Citizens: Patient Care or Profits?
Makowsky M, Legal GM, Buchkowsky SS, Koshman SL, Jewesson PJ

Evidence-Based Snapshots
with emphasis on rapid review of results

Clinical Efficacy of Three Common Treatments in Acute Otitis Externa in Primary Care: Randomised Controlled Trial

Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both?

Azithromycin for the Secondary Prevention of Coronary Heart Disease Events: The WIZARD Study

Evidence-Based Reviews of the Pharmacotherapeutic Literature
with emphasis on interpretation of the findings, designed to help practitioners put the findings into proper perspective

  • Serum Digoxin Concentrations and Outcomes in Patients with Heart Failure: Is There Any Association?
  • Robert McCollom
  • Blood Pressure Lowering or Just Candesartan in Acute Ischemic Stroke? The ACCESS Trial
  • Peter Loewen
  • Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients: Impact for Future Clinical Practice Guidelines?
  • Glen Pearson

Technology in Practice
helping pharmacotherapy practitioners use technology to enhance their practice

Securing Confidential Data On Your Personal Digital Assistant (PDA): Part 1. Using The Security Options Built Into The Palm Operating System
Gwen Liu, Robert M. Balen
Submit a question or topic suggestion!

Research Abstracts
rapid dissemination of research findings

Faculty of Pharmaceutical Sciences, University of British Columbia Alan C. Hayman Summer Student Research Competition 2003 (Partial Proceedings)

Non-Nucleoside Reverse-Transcriptase Inhibitor (NNRTI)-Induced Hepatotoxicity: Treatment Risk in an HIV+, Hepatitis C+, Injection Drug-Using Population
Rita M. Sheena, Jack da Silva, Mark W. Tyndall

Effects of Hospital Pharmacist Intervention on Non-Steroidal Anti-inflammatory Drug Use Following Hospital Discharge (INSTEAD)
Tila Pelletier, Peter Loewen. Kerry Wilbur

Study of Pantoprazole Intravenous Therapy in Acute Upper Gastrointestinal Bleeding (SPIT 2)
Mandeep K. Saran, Peter S. Loewen, Peter J. Zed

Evaluation of an Anticoagulation Protocol to Prolong Filter Life During Continuous Veno-venous Hemodiafiltration
Karmin G. Ip, Sean K. Gorman, Jane de Lemos, Richard S. Slavik

An Assessment of the Appropriateness of Published Pediatric Dosage Guidelines for Low Molecular Weight Heparin (Enoxaparin) in a Tertiary Care Institution
Sharon H Ho, John K Wu, Donald P Hamilton, David B Dix, and Louis D Wadsworth

Evaluation of the Efficiency of Pharmacy Clinical Technician in the Antibiotic Intravenous to Oral Conversion at St. Paul’s Hospital
T. Doris Leung, Glen Brown, Lee Ann McKenzie

An Evaluation Of Pharmacist Managed Anti-Coagulation Monitoring In Hemodialysis Patients
Mildred Tang, Joanne Jung, Glen Brown

Microbiological Quality Control Study For The Purpose Of Extending The Use Of Transfer Sets On Automated Total Nutrient Admixture Compounding Pumps
Kenneth Chung, Greg Head

Microbiological Quality Control Study For The Purpose Of Extending The Use Of Transfer Sets On Automated Total Nutrient Admixture Compounding Pumps
Vicki Wong, Zahra Kanji, Rajesh Mainra, Michael Boldt

Use Of Alteplase (Tpa) In Restoration Of Hemodialysis Catheter Patency: An Evaluation Of Push Versus Dwell Method
T Cham, JM MacRae, S Shalansky, G Loh, M Kiaii, J Jung

Health Beliefs as Predictors of Non-adherence with Heart Failure Medications
Phuong Hoang, Stephen Shalansky, Andrew Ignaszewski, Wolfgang Linden, Adrian Levy, Biljana Radulovic

Drugs & Conditions